{{Rsnum
|rsid=41291556
|Gene=CYP2C19
|Chromosome=10
|position=96535173
|Orientation=plus
|ReferenceAllele=T
|MissenseAllele=C
|GMAF=0.001837
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|Summary=Clopidogrel (Plavix®)
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{CPMC SNP
|link=https://cpmc.coriell.org/Sections/Results/Plavix.aspx?PgId=212
}}
Defines the [[CYP2C19]] variant known as CYP2C19*8.

Carriers of the [[rs41291556]](C) allele may have decreased activity and poor metabolizer (PM) phenotype. This variant is associated with a dramatic (approximately 90% and 70%) reduction in the metabolism of S-mephenytoin and tolbutamide in vitro.{{PMID|10411572}}

{{PharmGKB
|RSID=rs41291556
|Name_s=CYP2C19:358T>C; 12711T>C; W120R; T358C
|Gene_s=CYP2C19
|Feature=Exon
|Evidence=PubMed ID:10411572
|Annotation=This variant is the defining SNP for CYP2C19*8 and leads to decreased activity and poor metabolizer (PM) phenotype.This variant is associated with a dramatic (approximately 90% and 70%) reduction in the metabolism of S-mephenytoin and tolbutamide in vitro.
|Drugs=mephenytoin; tolbutamide
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA162355683
}}

{{GET Evidence
|gene=CYP2C19
|aa_change=Trp120Arg
|aa_change_short=W120R
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs41291556
|overall_frequency_n=1
|overall_frequency_d=128
|overall_frequency=0.0078125
|n_genomes=1
|n_genomes_annotated=0
|n_haplomes=1
|n_articles=0
|n_articles_annotated=0
|pph2_score=1.0
|nblosum100=7
|autoscore=2
|webscore=N
}}

[[Clopidogrel Efficacy]]

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}